Brendan Frett

High Impact

Assistant Professor

University of Arkansas for Medical Sciences

faculty

Pharmaceutical Science, College of Pharmacy

BAFrett@uams.edu

23 h-index 135 pubs 1,399 cited

Research Areas

Cancer Treatment and Pharmacology Pharmacological Effects and Toxicity Studies Drug-Induced Hepatotoxicity and Protection Cancer-related molecular mechanisms research Computational Drug Discovery Methods Receptor Mechanisms and Signaling Protein Degradation and Inhibitors

Links

ORCID Lab Website UAMS TRI Profile

Is this your profile? Verify and claim your profile

OverviewAI-generated summary

Dr. Brendan Frett's research focuses on the discovery and development of small-molecule inhibitors for various kinases, particularly those implicated in cancer. His work involves the design, synthesis, and biological evaluation of novel chemical entities aimed at targeted cancer therapies. He has investigated inhibitors for rearranged during transfection (RET), tropomysin receptor kinase (TRK), and FMS-like tyrosine kinase 3 (FLT3) kinases, which are relevant to acute myeloid leukemia and other cancers.

His publications detail the structure-based optimization of these inhibitors, exploring their binding poses and potential for clinical development. Dr. Frett's research is translational, with an interest in moving academic discoveries toward clinical application to benefit patients. He maintains collaborations with researchers at the University of Arkansas for Medical Sciences, including Baku Acharya, Samantha Kendrick, Ying-Zhi Xu, and Mason McCrury, with whom he has co-authored numerous publications.

Dr. Frett earned his Ph.D. in Pharmaceutical Sciences from the University of Arizona. His scholarship metrics include an h-index of 23, 135 total publications, and 1,399 total citations. He is recognized as a highly cited researcher.

Research Overview

Dr. Brendan Frett received his Ph.D. in Pharmaceutical Sciences with an emphasis in Drug Discovery and Development from the University of Arizona in 2014. He received postdoctoral training in Medicinal Chemistry as well as Pharmaceutics at the University of Arizona. Dr. Frett has successfully transferred academic-based discoveries to pharmaceutical companies for clinical development. He is interested in pursuing translational research projects, where research completed in his laboratory can directly help patients.

Metrics

  • h-index: 23
  • Publications: 135
  • Citations: 1,399

Selected Publications

  • Discovery of N-(3-fluorophenyl)-2-(4-((7-(1-methyl-1H-pyrazol-4-yl)quinazolin-4-yl)amino)phenyl)acetamide as the first orally active selective aurora kinase B inhibitor (2025) DOI
  • Discovery of the DNA-PKcs inhibitor DA-143 which exhibits enhanced solubility relative to NU7441 (2024) DOI
  • Discovery of 9H-pyrimido[4,5-b]indole derivatives as dual RET/TRKA inhibitors (2024) DOI
  • Enhancer‐activated <scp>RET</scp> confers protection against oxidative stress to <scp>KMT2A</scp>‐rearranged acute myeloid leukemia (2024) DOI
  • Kinase inhibitor macrocycles: a perspective on limiting conformational flexibility when targeting the kinome with small molecules (2023) DOI
  • 443 Team Science (2023) DOI
  • An updated patent review of rearranged during transfection (RET) kinase inhibitors (2016–present) (2022) DOI
  • FLT3 inhibitors for acute myeloid leukemia: successes, defeats, and emerging paradigms (2022) DOI
  • Targeting a Novel G-Quadruplex in the CARD11 Oncogene Promoter with Naptho(2,1-b)furan-1-ethanol,2-nitro- Requires the Nitro Group (2022) DOI
  • Targeting TGF-β: Triumphs and Challenges (2022) DOI
  • Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose (2022) DOI
  • Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development (2021) DOI
  • Discovery of imidazo[1,2-a]pyridine-thiophene derivatives as FLT3 and FLT3 mutants inhibitors for acute myeloid leukemia through structure-based optimization of an NEK2 inhibitor (2021) DOI
  • Discovery of 4-aminoquinolines as highly selective TGFβR1 inhibitors with an attenuated MAP4K4 profile for potential applications in immuno-oncology (2021) DOI
  • Targeted activity of the small molecule kinase inhibitor Pz-1 towards RET and TRK kinases (2021) DOI

Grants & Funding

  • Center for Studies of Host Response to Cancer Therapy NIH Co-Investigator
  • Selective RET Kinase and Its Mutant Inhibitors for the Treatment of Medullary Thyroid Cancer NIH Co-Investigator
  • Center for Molecular Interactions in Cancer (CMIC) NIH Co-Investigator

Collaborators

Researchers in the database who share publications

Baku Acharya University of Arkansas for Medical Sciences 41 shared publications Samantha Kendrick University of Arkansas for Medical Sciences 33 shared publications Ying-Zhi Xu University of Arkansas for Medical Sciences 33 shared publications Mason McCrury University of Arkansas for Medical Sciences 33 shared publications Kennith Swafford University of Arkansas for Medical Sciences 33 shared publications Vijay Patel University of Arkansas for Medical Sciences 32 shared publications Donghoon Yoon University of Arkansas for Medical Sciences 32 shared publications Ginell R. Post University of Arkansas for Medical Sciences 32 shared publications

Similar Researchers

Based on overlapping research topics

Baku Acharya University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology Pharmacological Effects and Toxicity Studies Drug-Induced Hepatotoxicity and Protection
Good match 5 shared topics
Hong-yu Li University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology Pharmacological Effects and Toxicity Studies Cancer-related molecular mechanisms research
Good match 4 shared topics
Maha Hanafi University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology Cancer-related molecular mechanisms research Computational Drug Discovery Methods
Good match 4 shared topics
Phuc Tran University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology Pharmacological Effects and Toxicity Studies Computational Drug Discovery Methods
Good match 4 shared topics
Kate Steed University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology Pharmacological Effects and Toxicity Studies Drug-Induced Hepatotoxicity and Protection
Good match 3 shared topics
Anupreet Kharbanda University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology Pharmacological Effects and Toxicity Studies Cancer-related molecular mechanisms research
Good match 4 shared topics